Cancer Research UK 
Welcome,         Profile    Billing    Logout  
 13 Products   2 Diseases  13 Products   7 Trials   326 News 
13 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMA950 / Immatics, University Hospitals of Geneva
IMA950-106, NCT03665545: Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

Completed
1/2
18
Europe
IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab
University Hospital, Geneva
Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
12/23
04/24
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated
1
14
US
IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127
Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
12/22
12/22
VAC2 / Cancer Research UK, Lineage Cell Therap
CRUKD/17/003, NCT03371485: AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

Completed
1
9
Europe
AST-VAC2
Cancer Research UK
Advanced Non-small Cell Lung Cancer
08/22
08/22
VTP-600 / Barinthus Bio
CRUKD/20/001, NCT04908111: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Suspended
1/2
15
Europe
ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment, MVA-NYESO (Route = IM injection, Dose = 1.5×10^8 pfu)
Cancer Research UK, Vaccitech Oncology Ltd (VOLT)
Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer
09/24
03/29
TT-702 / Teon Therap
CURATE, NCT05272709: TT-702 in Patients With Advanced Solid Tumours.

Recruiting
1/2
188
Europe
TT-702, Darolutamide
Cancer Research UK, Teon Therapeutics, Inc.
Advanced Solid Tumors
06/27
06/27
CAL101 / Calluna Pharma
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Completed
1
58
Europe
Placebo, AX-202
Arxx Therapeutics
Healthy Volunteers, Mild to Moderate Psoriasis
07/24
07/24
budoprutug (TNT119) / Climb Bio
NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Terminated
2
1
US
VB119
Tenet Medicines
Minimal Change Disease, Focal Segmental Glomerulosclerosis
05/23
10/23
NCT04652570: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

Active, not recruiting
1/2
6
US
VB119
Tenet Medicines
Membranous Nephropathy
11/23
08/24
NCT06570434: Phase 1b/2a in SLE With Budoputug

Withdrawn
1/2
40
NA
budoprutug
Tenet Medicines
Systemic Lupus Erythematosus, SLE, B Cells
12/26
04/27
NCT07043946: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Recruiting
1/2
24
RoW
Budoprutug, TNT119
Climb Bio, Inc.
Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19
08/27
08/28
NCT07011043: A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Recruiting
1
30
US, RoW
Budoprutug, TNT119
Climb Bio, Inc.
Systemic Lupus Erythematosus
04/27
04/27
NXE0039732 / Nxera Pharma
NCT05944237: HTL0039732 in Participants With Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Nxera Pharma UK Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
06/27
06/27
MOv18 IgE / Epsilogen, Cancer Research UK
EPS101-10-02, NCT06547840: A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer

Recruiting
1
45
Europe
MOv18 IgE
Epsilogen Ltd
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
07/26
03/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
IMA950 / Immatics, University Hospitals of Geneva
IMA950-106, NCT03665545: Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma

Completed
1/2
18
Europe
IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab
University Hospital, Geneva
Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
12/23
04/24
NCT02924038: A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Terminated
1
14
US
IMA950, IMA950 peptides, poly-ICLC, Hiltonol, Varlilumab, CDX-1127
Nicholas Butowski, Celldex Therapeutics, National Cancer Institute (NCI)
Glioma, Malignant Glioma, Astrocytoma, Grade II, Oligodendroglioma, Glioma, Astrocytic, Oligoastrocytoma, Mixed
12/22
12/22
VAC2 / Cancer Research UK, Lineage Cell Therap
CRUKD/17/003, NCT03371485: AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer

Completed
1
9
Europe
AST-VAC2
Cancer Research UK
Advanced Non-small Cell Lung Cancer
08/22
08/22
VTP-600 / Barinthus Bio
CRUKD/20/001, NCT04908111: A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1

Suspended
1/2
15
Europe
ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment, MVA-NYESO (Route = IM injection, Dose = 1.5×10^8 pfu)
Cancer Research UK, Vaccitech Oncology Ltd (VOLT)
Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer
09/24
03/29
TT-702 / Teon Therap
CURATE, NCT05272709: TT-702 in Patients With Advanced Solid Tumours.

Recruiting
1/2
188
Europe
TT-702, Darolutamide
Cancer Research UK, Teon Therapeutics, Inc.
Advanced Solid Tumors
06/27
06/27
CAL101 / Calluna Pharma
NCT05965089: A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

Completed
1
58
Europe
Placebo, AX-202
Arxx Therapeutics
Healthy Volunteers, Mild to Moderate Psoriasis
07/24
07/24
budoprutug (TNT119) / Climb Bio
NCT05441826: Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)

Terminated
2
1
US
VB119
Tenet Medicines
Minimal Change Disease, Focal Segmental Glomerulosclerosis
05/23
10/23
NCT04652570: Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

Active, not recruiting
1/2
6
US
VB119
Tenet Medicines
Membranous Nephropathy
11/23
08/24
NCT06570434: Phase 1b/2a in SLE With Budoputug

Withdrawn
1/2
40
NA
budoprutug
Tenet Medicines
Systemic Lupus Erythematosus, SLE, B Cells
12/26
04/27
NCT07043946: A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

Recruiting
1/2
24
RoW
Budoprutug, TNT119
Climb Bio, Inc.
Immune Thrombocytopenia (ITP), ITP, Biologics, Monoclonal, Anti-CD19
08/27
08/28
NCT07011043: A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

Recruiting
1
30
US, RoW
Budoprutug, TNT119
Climb Bio, Inc.
Systemic Lupus Erythematosus
04/27
04/27
NXE0039732 / Nxera Pharma
NCT05944237: HTL0039732 in Participants With Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Nxera Pharma UK Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
06/27
06/27
MOv18 IgE / Epsilogen, Cancer Research UK
EPS101-10-02, NCT06547840: A Study of MOv18 IgE in Folate Receptor Alpha-expressing Platinum Resistant Ovarian Cancer

Recruiting
1
45
Europe
MOv18 IgE
Epsilogen Ltd
Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer
07/26
03/27

Download Options